Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Licenses ZFN Gene Editing Technology from Sigma-Aldrich

Published: Tuesday, September 03, 2013
Last Updated: Tuesday, September 03, 2013
Bookmark and Share
Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line generation services and creation of genetically-defined cell line products.

Horizon Discovery (Horizon) has announced that it has entered into a non-exclusive license agreement with Sigma-Aldrich (Sigma) for use of their CompoZr ® zinc finger nuclease (ZFN) technology.

The deal gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene-editing service and cell line product business units.

Horizon will immediately begin using ZFN technology as part of its unique custom cell line generation service, where both ZFN and rAAV technologies will be applied, either independently or in combination, to deliver the full spectrum of genomic modifications as efficiently and cost-effectively as possible.

The offering will be marketed under Horizon’s precision gene-editing brand GENESIS™.

Dr Darrin Disley, CEO of Horizon, said: “Horizon is a full service translational genomics company with its business activities encompassing the identification of the genetic drivers of disease, the creation of human disease models and their deployment in the development of targeted molecular therapeutics. I am delighted that we can now apply both ZFN and rAAV gene editing to give our customers a gold standard and technology agnostic cell-line generation service.”

Eric Rhodes, CTO of Horizon who has 15 years’ experience in ZFN and rAAV gene-editing technology, said: “Nuclease based approaches are particularly adept at achieving rapid and efficient knock-out of two or more alleles, making them a perfect complement to Horizon’s proprietary rAAV-based precision gene-editing platform. Our scientists have the expertise and now an unrivalled toolset to help guide customers towards the approach that best answers their biological question and/or suits their timescale and budget.”

Dr Paul Brooks, Global Market Segment Manager at Sigma Life Science, commented: “We are pleased that Horizon will be using their expertise to apply both gene editing technologies side by side for the benefit of the research community. The exploitation of these proven technologies is a key step in capitalizing on the wealth of genomic information now available, and in applying this to real drug discovery and development programs.”

Under the terms of the deal, Horizon will obtain ZFNs manufactured by Sigma for use in commercial development of cell based products and to provide commercial gene editing services.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Fulcrum Launch Collaboration
Horizon Discovery and Fulcrum Therapeutics form collaboration for novel CRISPR-based target discovery in genetic diseases.
Tuesday, September 06, 2016
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Acquires Sage Labs Inc. for $48M (£29M)
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company.
Wednesday, October 01, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.
Thursday, January 30, 2014
Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
Chairman’s healthcare industry career spans thirty years, encompassing all aspects of successful company growth and development.
Tuesday, January 14, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Discovery CEO Joins UKTI Delegation to India Led by David Cameron
Senior business and political leaders from India and Europe meet at Prabodhan Leaders’ Conclave.
Tuesday, November 26, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Probe Identifies Schizophrenia Genes That Stunt Brain Development
Scientists have isolated schizophrenia-related gene variants that change gene expression in the brain.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!